+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men



Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men



Sexual Health 12(3): 240-248



Background Although it significantly improves HIV-related outcomes, some components of combination antiretroviral therapy (ART) cause lipodystrophy syndrome. The composition of combination ART has changed over time but the impact on lipodystrophy prevalence is unknown. One hundred HIV-infected males underwent dual-energy X-ray absorptiometry scanning, serum lipid testing and completed a questionnaire in a cross-sectional study in 2010. Thirty-four participants of a 1998 study cohort were re-evaluated in 2010. The same parameters were used to define and compare lipodystrophy, metabolic syndrome and cardiovascular disease (CVD) risk in the two time periods. In 2010, the prevalence of lipodystrophy was lower when compared with 1998 (53% v. 69%, P=0.012), despite higher mean age (51.8 v. 42.1 years, P<0.0001), duration of HIV (165 v. 86 months, P<0.0001), ART exposure (129 v. 38 months, P<0.0001), CD4+ cell count (601 v. 374 cells µL(-1), P<0.0001) and waist circumference (95.5 v. 89.9cm P<0.0001). Cholesterol (5.0 v. 5.6mmolL(-1), P=0.0001) and triglycerides (1.9 v. 3.7mmolL(-1), P<0.0001) were significantly lower in 2010. Factors associated with an increased risk of lipodystrophy in 2010 were duration of HIV infection and low-density lipoprotein cholesterol, whereas current tenofovir or abacavir use was associated with a decreased risk of lipodystrophy. On multivariate analysis low-density lipoprotein cholesterol (OR, 2.65; CI, 1.4-4.9) remained significant for an increased risk and current tenofovir or abacavir use with reduced risk of lipodystrophy (OR, 0.096; CI, 0.011-0.83). In 2010 there was a higher prevalence of metabolic syndrome (33 v. 28%) and higher median Framingham CVD risk (9.9% (5.7-14.6) v. 8.2% (4.5-12.9). Despite ageing and longer duration of HIV infection and ART exposure, the prevalence of lipodystrophy in HIV-infected men significantly declined over a 12-year period. However, a trend exists toward a higher prevalence of metabolic syndrome and increased CVD risk.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057381064

Download citation: RISBibTeXText

PMID: 27470913

DOI: 10.1071/SH14084


Related references

Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. International Journal of Immunopathology and Pharmacology 20(3): 519-527, 2007

Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors. Arquivos Brasileiros de Endocrinologia E Metabologia 52(4): 658-667, 2008

Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients. La Revue du Praticien 56(9): 987-994, 2006

High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. Journal of Acquired Immune Deficiency Syndromes 31(3): 363-365, 2002

Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients. Bmc Infectious Diseases 11: 246, 2011

Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome. Journal of Infection 62(3): 240-243, 2011

Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. Cardiovascular Diabetology 9: 34, 2010

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current Hiv/Aids Reports 2(3): 132-139, 2005

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis. European Journal of Rheumatology 4(1): 40-45, 2017

Prevalence of metabolic syndrome and cardiovascular disease risk factors in adults with cerebral palsy. Developmental Medicine and Child Neurology 2019, 2019

Evolving cardiovascular disease prevalence, mortality, risk factors, and the metabolic syndrome in China. Clinical Cardiology 32(9): 491-497, 2009

AB0766Increased Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk in Turkish Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases 73(Suppl 2): 1058.1-1058, 2014

High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda. Aids Patient Care and Stds 30(1): 4-10, 2016

Cardiovascular Risk Stratification in Patients with Metabolic Syndrome Without Diabetes or Cardiovascular Disease: Usefulness of Metabolic Syndrome Severity Score. High Blood Pressure and Cardiovascular Prevention 24(3): 297-303, 2017

The Cerebral Palsy Adult Transition Study: Metabolic Syndrome and Cardiovascular Disease Risk Factors Prevalence. Archives of Physical Medicine and Rehabilitation 98(10): E115-E116, 2017